Services-Testing Laboratories
Neogenomics Inc (NEO) stock: what's happening now, every material event decoded in plain English, P/E and valuation, analyst ratings, and insider buying and selling.
AllSight quality score: 36/100 — a percentile rank of Neogenomics Inc’s fundamentals against Services peers.
Is Neogenomics Inc overvalued? P/S looks fair vs its 5-year range; P/B looks overvalued vs its 5-year range.
Consensus: Buy from 30 analysts (Strong buy 1 · Buy 23 · Hold 5 · Sell 1).
Average price target: $22.60 (+49.8% vs $15.09); range $19–$28.
Wall Street analyst consensus, shown as context — not an AllSight view.
Open-market buys: 0 · Open-market sells: 1 · Net: −$321K
Discretionary open-market purchases are the signal; grants, option exercises and Rule 10b5-1 scheduled trades are context, not counted in the balance. Facts only — not a recommendation. Source: SEC Form 4 filings on EDGAR.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!